Conivaptan for the Reduction of Cerebral Edema in Intracerebral Hemorrhage- A Safety and Tolerability Study

PHASE1CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

March 22, 2017

Primary Completion Date

February 12, 2019

Study Completion Date

April 15, 2019

Conditions
Cerebral HemorrhageCerebral EdemaIntracerebral HemorrhageStroke
Interventions
DRUG

Conivaptan

"Patients will receive 20mg IV of the study drug every 12 hours equaling 40mg/day over 2 days (4 doses total), in addition to the standardized ICH management targets using the PI's version of standardized ICH management targets.Usual standard of care can include sedation and analgesia as needed, elevation of the head of the bed, mannitol and/or saline as needed to reduce ICP, and temperature control with antipyretics such as acetaminophen.~The conivaptan bolus (20mg), which is premixed with 100ml of 5% dextrose in water, is infused (peripherally) over 30 minutes, most commonly through an already placed central line."

Trial Locations (1)

55102

United Hospital, Saint Paul

All Listed Sponsors
lead

Jesse Corry

OTHER

NCT03000283 - Conivaptan for the Reduction of Cerebral Edema in Intracerebral Hemorrhage- A Safety and Tolerability Study | Biotech Hunter | Biotech Hunter